Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.

Cancer research - 1 Jul 2018

Ruiz-Saenz Ana, Dreyer Courtney, Campbell Marcia R, Steri Veronica, Gulizia Nate, Moasser Mark M

Abstract excerpt

Current evidence suggests that HER2-driven tumorigenesis requires HER3. This is likely due to the unique ability of HER3 to activate PI3K/Akt pathway signaling, which is not directly accessible to HER2. By genetic elimination of HER3 or shRNA knockdown of HER3 in HER2-amplified cancer cells, we find residual HER2-driven activation of PI3K/Akt pathway signaling that is driven by HER2 through direct and indirect...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Gene Knockout Techniques
Share to Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Receptor, ErbB-2

Share to Receptor, ErbB-3

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29760043
DOI: 10.1158/0008-5472.CAN-18-0430
PMCID: PMC6779043

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.PMID 29760043Read ↗

Understanding the biology of HER3 receptor as a therapeutic target in human cancerSemantic proximity Read ↗

Targeting HER proteins in cancer therapy and the role of the non-target HER3Semantic proximity Read ↗

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor ResponseSemantic proximity Read ↗

HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer.Semantic proximity Read ↗

Regulation of ERBB3/HER3 signaling in cancer.Semantic proximity Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.